FDA-approved drug screening in patient-derived organoids demonstrates potential of drug repurposing for rare cystic fibrosis genotypes

Autor: E. de Poel, S. Spelier, M.C. Hagemeijer, P. van Mourik, S.W.F. Suen, A.M. Vonk, J.E. Brunsveld, G.N. Ithakisiou, E. Kruisselbrink, H. Oppelaar, G. Berkers, K.M. de Winter de Groot, S. Heida-Michel, S.R. Jans, H. van Panhuis, M. Bakker, R. van der Meer, J. Roukema, E. Dompeling, E.J.M. Weersink, G.H. Koppelman, A.R. Blaazer, J.E. Muijlwijk-Koezen, C.K. van der Ent, J.M. Beekman

Publikováno v: Journal of cystic fibrosis. Elsevier
Journal of Cystic Fibrosis, 22, 548-559
Journal of Cystic Fibrosis, 22, 3, pp. 548-559
Journal of Cystic Fibrosis, 22(3), 548-559. Elsevier

Item does not contain fulltext BACKGROUND: Preclinical cell-based assays that recapitulate human disease play an important role in drug repurposing. We previously developed a functional forskolin induced swelling (FIS) assay using patient-derived int

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89ec4ff876b41ac455bf427f708ef3b6
https://pure.amc.nl/en/publications/fdaapproved-drug-screening-in-patientderived-organoids-demonstrates-potential-of-drug-repurposing-for-rare-cystic-fibrosis-genotypes(d3d6bd49-ebfc-40f4-ab6c-0e87380d8a5f).html

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.